Evogene Competitors

Evogene (NASDAQ:EVGN) and Nutrien (NYSE:NTR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.

Institutional and Insider Ownership

33.0% of Evogene shares are held by institutional investors. Comparatively, 61.9% of Nutrien shares are held by institutional investors. 3.1% of Nutrien shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Evogene has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Nutrien has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

Profitability

This table compares Evogene and Nutrien's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Evogene and Nutrien, as reported by MarketBeat.com.

Evogene currently has a consensus target price of $9.00, indicating a potential upside of 105.95%. Nutrien has a consensus target price of $56.4444, indicating a potential upside of 0.76%. Given Evogene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evogene is more favorable than Nutrien.

Earnings & Valuation

This table compares Evogene and Nutrien's gross revenue, earnings per share (EPS) and valuation.

Nutrien has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than Nutrien, indicating that it is currently the more affordable of the two stocks.

Summary

Nutrien beats Evogene on 11 of the 15 factors compared between the two stocks.

The Scotts Miracle-Gro (NYSE:SMG) and Evogene (NASDAQ:EVGN) are both basic materials companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Volatility & Risk

The Scotts Miracle-Gro has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Profitability

This table compares The Scotts Miracle-Gro and Evogene's net margins, return on equity and return on assets.

Insider & Institutional Ownership

63.1% of The Scotts Miracle-Gro shares are owned by institutional investors. Comparatively, 33.0% of Evogene shares are owned by institutional investors. 27.2% of The Scotts Miracle-Gro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for The Scotts Miracle-Gro and Evogene, as reported by MarketBeat.com.

The Scotts Miracle-Gro currently has a consensus target price of $250.00, indicating a potential upside of 4.94%. Evogene has a consensus target price of $9.00, indicating a potential upside of 105.95%. Given Evogene's higher probable upside, analysts clearly believe Evogene is more favorable than The Scotts Miracle-Gro.

Valuation & Earnings

This table compares The Scotts Miracle-Gro and Evogene's top-line revenue, earnings per share and valuation.

The Scotts Miracle-Gro has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than The Scotts Miracle-Gro, indicating that it is currently the more affordable of the two stocks.

Summary

The Scotts Miracle-Gro beats Evogene on 12 of the 15 factors compared between the two stocks.

Evogene (NASDAQ:EVGN) and The Mosaic (NYSE:MOS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Insider & Institutional Ownership

33.0% of Evogene shares are held by institutional investors. Comparatively, 69.8% of The Mosaic shares are held by institutional investors. 0.5% of The Mosaic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Evogene and The Mosaic's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations and price targets for Evogene and The Mosaic, as reported by MarketBeat.com.

Evogene presently has a consensus target price of $9.00, suggesting a potential upside of 105.95%. The Mosaic has a consensus target price of $27.9722, suggesting a potential downside of 16.40%. Given Evogene's stronger consensus rating and higher probable upside, analysts plainly believe Evogene is more favorable than The Mosaic.

Valuation & Earnings

This table compares Evogene and The Mosaic's gross revenue, earnings per share (EPS) and valuation.

Evogene has higher earnings, but lower revenue than The Mosaic. Evogene is trading at a lower price-to-earnings ratio than The Mosaic, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Evogene has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, The Mosaic has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500.

Summary

The Mosaic beats Evogene on 9 of the 14 factors compared between the two stocks.

Evogene (NASDAQ:EVGN) and CF Industries (NYSE:CF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.

Valuation & Earnings

This table compares Evogene and CF Industries' gross revenue, earnings per share and valuation.

CF Industries has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than CF Industries, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

33.0% of Evogene shares are held by institutional investors. Comparatively, 91.0% of CF Industries shares are held by institutional investors. 2.0% of CF Industries shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Evogene and CF Industries, as provided by MarketBeat.

Evogene presently has a consensus price target of $9.00, indicating a potential upside of 105.95%. CF Industries has a consensus price target of $43.9167, indicating a potential downside of 7.17%. Given Evogene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Evogene is more favorable than CF Industries.

Volatility and Risk

Evogene has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, CF Industries has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.

Profitability

This table compares Evogene and CF Industries' net margins, return on equity and return on assets.

Summary

CF Industries beats Evogene on 10 of the 14 factors compared between the two stocks.

ICL Group (NYSE:ICL) and Evogene (NASDAQ:EVGN) are both basic materials companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Earnings & Valuation

This table compares ICL Group and Evogene's gross revenue, earnings per share (EPS) and valuation.

ICL Group has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than ICL Group, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

7.4% of ICL Group shares are owned by institutional investors. Comparatively, 33.0% of Evogene shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

ICL Group has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Profitability

This table compares ICL Group and Evogene's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for ICL Group and Evogene, as provided by MarketBeat.

ICL Group currently has a consensus price target of $5.75, suggesting a potential downside of 10.85%. Evogene has a consensus price target of $9.00, suggesting a potential upside of 105.95%. Given Evogene's stronger consensus rating and higher probable upside, analysts clearly believe Evogene is more favorable than ICL Group.

Summary

ICL Group beats Evogene on 7 of the 13 factors compared between the two stocks.

American Vanguard (NYSE:AVD) and Evogene (NASDAQ:EVGN) are both small-cap basic materials companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Volatility & Risk

American Vanguard has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.

Institutional and Insider Ownership

76.5% of American Vanguard shares are held by institutional investors. Comparatively, 33.0% of Evogene shares are held by institutional investors. 5.3% of American Vanguard shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares American Vanguard and Evogene's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings for American Vanguard and Evogene, as provided by MarketBeat.com.

Evogene has a consensus price target of $9.00, indicating a potential upside of 105.95%. Given Evogene's higher possible upside, analysts plainly believe Evogene is more favorable than American Vanguard.

Valuation & Earnings

This table compares American Vanguard and Evogene's top-line revenue, earnings per share (EPS) and valuation.

American Vanguard has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than American Vanguard, indicating that it is currently the more affordable of the two stocks.

Summary

American Vanguard beats Evogene on 9 of the 13 factors compared between the two stocks.